• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019 - 2020年发表的临床试验中复合结局所致偏倚的患病率:一项系统评价。

Prevalence of bias attributable to composite outcome in clinical trials published in 2019-2020: a systematic review.

作者信息

Silva José Mário Nunes da, Conceição Juliana Ferreira Souza, Ramírez Paula Camila, Diaz-León Christian Leonardo, Diaz-Quijano Fredi Alexander

机构信息

Universidade de São Paulo, School of Public Health, Graduate Program in Epidemiology - São Paulo (SP), Brazil.

Universidade de São Paulo, School of Public Health - São Paulo (SP), Brazil.

出版信息

Rev Bras Epidemiol. 2025 Jun 27;28:e250035. doi: 10.1590/1980-549720250035. eCollection 2025.

DOI:10.1590/1980-549720250035
PMID:40608574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12204237/
Abstract

OBJECTIVE

The aim of this study was to investigate the prevalence of bias attributable to composite outcome (BACO) in clinical trials.

METHODS

We searched PubMed for randomized clinical trials where the primary outcome was a binary composite that included all-cause mortality among its components from January 1, 2019, to December 31, 2020. For each trial, the BACO index was calculated to assess the correspondence between effects on the composite outcome and mortality. This systematic review was registered in PROSPERO (CRD42021229554).

RESULTS

After screening 1,076 citations and 171 full-text articles, 91 studies were included from 13 different medical areas. The prevalence of significant or suggestive BACO among the 91 included articles was 25.2% (n=23), including 12 with p<0.005 and 11 with p between 0.005 and <0.05. We observed that in 17 (73.9%) of these 23 studies, the BACO index value was between 0 and <1, indicating an underestimation of the effect. The other six studies showed negative values (26.1%), indicating an inversion of the association with mortality. None of the studies showed significant overestimation of the association attributable to the composite outcome.

CONCLUSION

These findings highlight the need to predefine guidelines for interpreting effects on composite endpoints based on objective criteria such as the BACO index.

摘要

目的

本研究旨在调查临床试验中复合结局所致偏倚(BACO)的发生率。

方法

我们在PubMed中检索了2019年1月1日至2020年12月31日期间以二元复合结局为主要结局且其组成部分包括全因死亡率的随机临床试验。对于每项试验,计算BACO指数以评估对复合结局的效应与死亡率之间的对应关系。该系统评价已在PROSPERO(CRD42021229554)中注册。

结果

在筛选了1076篇引文和171篇全文文章后,纳入了来自13个不同医学领域的91项研究。在纳入的91篇文章中,显著或提示性BACO的发生率为25.2%(n = 23),其中12篇p<0.005,11篇p在0.005至<0.05之间。我们观察到,在这23项研究中的17项(73.9%)中,BACO指数值在0至<1之间,表明效应被低估。其他6项研究显示为负值(26.1%),表明与死亡率的关联发生了反转。没有研究显示因复合结局导致的关联被显著高估。

结论

这些发现凸显了需要基于诸如BACO指数等客观标准预先制定解释对复合终点效应的指南。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ae9/12204237/f127f1c962b5/1980-5497-rbepid-28-e250035-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ae9/12204237/f127f1c962b5/1980-5497-rbepid-28-e250035-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ae9/12204237/f127f1c962b5/1980-5497-rbepid-28-e250035-gf01.jpg

相似文献

1
Prevalence of bias attributable to composite outcome in clinical trials published in 2019-2020: a systematic review.2019 - 2020年发表的临床试验中复合结局所致偏倚的患病率:一项系统评价。
Rev Bras Epidemiol. 2025 Jun 27;28:e250035. doi: 10.1590/1980-549720250035. eCollection 2025.
2
Interventions for paracetamol (acetaminophen) overdose.对乙酰氨基酚过量的干预措施。
Cochrane Database Syst Rev. 2018 Feb 23;2(2):CD003328. doi: 10.1002/14651858.CD003328.pub3.
3
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
4
Education support services for improving school engagement and academic performance of children and adolescents with a chronic health condition.改善患有慢性病的儿童和青少年的学校参与度和学业成绩的教育支持服务。
Cochrane Database Syst Rev. 2023 Feb 8;2(2):CD011538. doi: 10.1002/14651858.CD011538.pub2.
5
Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection.基于人群的生物医学性传播感染控制干预措施以减少艾滋病毒感染。
Cochrane Database Syst Rev. 2011 Mar 16(3):CD001220. doi: 10.1002/14651858.CD001220.pub3.
6
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
7
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.成人伴或不伴有广场恐惧症的惊恐障碍的心理治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 Apr 13;4(4):CD011004. doi: 10.1002/14651858.CD011004.pub2.
8
Incentives for preventing smoking in children and adolescents.预防儿童和青少年吸烟的激励措施。
Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD008645. doi: 10.1002/14651858.CD008645.pub3.
9
Hydromorphone for cancer pain.氢吗啡酮用于癌症疼痛。
Cochrane Database Syst Rev. 2016 Oct 11;10(10):CD011108. doi: 10.1002/14651858.CD011108.pub2.
10
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.用于治疗符合抗逆转录病毒治疗条件的孕妇艾滋病毒感染的抗逆转录病毒疗法。
Cochrane Database Syst Rev. 2010 Mar 17(3):CD008440. doi: 10.1002/14651858.CD008440.

本文引用的文献

1
Composite endpoints in COVID-19 randomized controlled trials: a systematic review.COVID-19随机对照试验中的复合终点:一项系统评价
Clin Trials. 2025 Feb;22(1):77-87. doi: 10.1177/17407745241276130. Epub 2024 Oct 10.
2
The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials.JBI 偏倚风险评估工具修订版用于评估随机对照试验的偏倚风险。
JBI Evid Synth. 2023 Mar 1;21(3):494-506. doi: 10.11124/JBIES-22-00430.
3
Bias attributable to the use of a composite outcome in evaluating a cocoa extract supplement.
在评估可可提取物补充剂时,因使用复合结局而产生的偏倚。
Am J Clin Nutr. 2022 Nov;116(5):1452. doi: 10.1093/ajcn/nqac185. Epub 2023 Feb 10.
4
Using a Composite Outcome in Estimating the Effect of Co-trimoxazole Prophylaxis on Prognosis in African Adults Receiving Antiretroviral Therapy.在评估复方新诺明预防对接受抗逆转录病毒治疗的非洲成年人预后的影响时使用复合结局指标。
Clin Infect Dis. 2021 Oct 20;73(8):1550-1551. doi: 10.1093/cid/ciab362.
5
Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial.重新审视抗逆转录病毒治疗时代非洲成人复方新诺明预防应用:一项随机对照临床试验。
Clin Infect Dis. 2021 Sep 15;73(6):1058-1065. doi: 10.1093/cid/ciab252.
6
Estimating and testing an index of bias attributable to composite outcomes in comparative studies.在比较研究中估计和检验归因于复合结局的偏倚指数。
J Clin Epidemiol. 2021 Apr;132:1-9. doi: 10.1016/j.jclinepi.2020.12.003. Epub 2020 Dec 9.
7
Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.复方新诺明(甲氧苄啶-磺胺甲噁唑)与安慰剂对中重度特发性肺纤维化患者死亡、肺移植或住院的影响:EME-TIPAC 随机临床试验。
JAMA. 2020 Dec 8;324(22):2282-2291. doi: 10.1001/jama.2020.22960.
8
Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.高剂量三价流感疫苗与标准剂量四价流感疫苗对伴有高危心血管疾病患者的死亡率或心肺住院率的影响:一项随机临床试验。
JAMA. 2021 Jan 5;325(1):39-49. doi: 10.1001/jama.2020.23649.
9
Task Shifting for Initiation and Monitoring of Antiretroviral Therapy for HIV-Infected Adults in Uganda: The SHARE Trial.在乌干达为感染 HIV 的成年人启动和监测抗逆转录病毒治疗的任务转移:SHARE 试验。
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e71-e79. doi: 10.1097/QAI.0000000000002567.
10
Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial.围生期心肌病患者的硒补充:一项概念验证试验。
BMC Cardiovasc Disord. 2020 Oct 21;20(1):457. doi: 10.1186/s12872-020-01739-z.